4F-PCC用于华法林相关脑出血且基线GCS≤8患者的临床结局
本研究为在综合性卒中中心开展的回顾性病历审查,纳入2013年10月至2020年8月期间年龄≥18岁、自发性脑出血且基线GCS≤8、入院前使用华法林、基线INR≥1.7并因华法林相关脑出血接受4F-PCC以逆转INR的患者。共252例患者接受4F-PCC,其中25例符合纳入标准;主要终点为30天院内死亡率,16例(64%)发生院内死亡。与所研究人群历史估计80%死亡率相比,使用4F-PCC逆转INR后死亡率无统计学显著差异(p=0.208)。作者认为,尽管结果未达统计学显著,这项小型研究提示4F-PCC可能带来临床显著的死亡率获益,但受研究设计和样本量限制,需更大规模研究确定。
要点
- 25例华法林相关ICH且基线GCS≤8患者接受4F-PCC逆转INR,16例(64%)发生院内死亡。
- 与历史估计80%死亡率相比,4F-PCC组死亡率无统计学显著差异(p=0.208)。
- 作者认为,尽管未达统计学显著,这项小型研究提示4F-PCC可能带来临床显著的死亡率获益。
- 研究受研究设计和样本量限制,作者提出需更大规模研究确定4F-PCC在该人群是否存在获益。
适用人群与场景
- 年龄≥18岁、自发性脑出血且基线GCS≤8、入院前使用华法林、基线INR≥1.7,并因华法林相关脑出血接受4F-PCC以逆转INR的患者。
- 研究在综合性卒中中心开展,纳入时间为2013年10月至2020年8月。
诊断标准与关键阈值
- 纳入标准:年龄≥18岁;自发性ICH;基线GCS≤8;入院前使用华法林;基线INR≥1.7;因华法林相关ICH接受4F-PCC以逆转INR。
研究设计与关键结果
- 研究类型:回顾性病历审查;地点:综合性卒中中心;时间:2013年10月至2020年8月;共252例患者接受4F-PCC,其中25例符合纳入标准。
- 主要终点:30天院内死亡率;25例中16例(64%)发生院内死亡。
- 与所研究人群历史估计80%死亡率相比,使用4F-PCC逆转INR后死亡率无统计学显著差异(p=0.208)。
证据类型、等级与局限
- 证据类型:回顾性病历审查。
- 局限:研究受研究设计和样本量限制;作者提出需更大规模研究确定4F-PCC在该人群是否存在获益。
对床旁实践的改变
- 作者认为,尽管结果未达统计学显著,这项小型研究提示4F-PCC用于华法林相关ICH且GCS≤8患者可能带来临床显著的死亡率获益,但需更大规模研究确定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: There is limited evidence describing the mortality benefit of utilizing 4-factor prothrombin complex concentrate (4F-PCC) in patients presenting with a warfarin-associated intracerebral hemorrhage (ICH) and a Glasgow Coma Scale (GCS) of ≤8. The aim of this study is to determine the potential mortality benefit of 4F-PCC in this patient population.
METHODS: This was a retrospective chart review, performed at a comprehensive stroke center from October 2013 through August 2020. Patients were included if they were ≥ 18 years of age, experienced a spontaneous ICH with baseline GCS ≤ 8, treated with warfarin prior to admission, had a baseline INR ≥ 1.7, and received 4F-PCC for INR normalization due to warfarin-associated ICH. The primary outcome was in-hospital mortality at 30 days.
RESULTS: A total of 252 patients received 4F-PCC in the specified time period. Of those patients, 25 patients met inclusion criteria. Sixteen patients (64%) experienced in-hospital mortality. When compared to a historical estimated 80% mortality rate in the studied patient population, there was no statistically significant difference (p = 0.208) in mortality when 4F-PCC was utilized to reverse INR.
CONCLUSION: The administration of 4F-PCC in patients presenting with warfarin-related ICH and GCS ≤ 8 did not result in statistically significant mortality benefit. Our results are limited by study design and sample size. Thus, larger studies are needed to determine if a benefit exists for 4F-PCC in this patient population. Although the results are not statistically significant, our small study suggests that there may be a clinically significant mortality benefit when 4F-PCC is utilized.
参考来源
- Koehl KE, Panos NG, Peksa GD, et al. Clinical outcomes after 4F-PCC for warfarin-associated ICH and baseline GCS less than or equal to 8. Am J Emerg Med. 2022. PMID: 35785611. doi:10.1016/j.ajem.2022.06.041
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。